

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

APPOINTMENT OF EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sinopharm Tech Holdings Limited (the “**Company**”) is pleased to announce that Mr. CHIU Sin Nang Kenny (“**Mr. CHIU**”) has been appointed as an executive Director and a member of the nomination committee and the remuneration committee of the Company with effect from 2 June 2025. The Board further announces that Ms. KWOK Shuk Yi has resigned as a member of the nomination committee of the Company with effect from 2 June 2025. Mr. CHIU’s biographical details are set out below:

Mr. CHIU Sin Nang Kenny, aged 63, is a professional accountant (FCPA) in Hong Kong and Australia, with over 35 years of experience in financial accounting and corporate management. Mr. CHIU currently serves as a non-executive director of Hua Yin International Holdings Limited (Stock Code: 0989), the securities of which are listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and a director of the Hong Kong International Family Office Limited. He has previously held executive director position at Kin Shing Holdings Limited (Stock Code: 1630), the securities of which are listed on the Stock Exchange and independent non-executive director positions in various listed companies the securities of which are listed on the Stock Exchange, including Keyne Limited (“**Keyne**”) (formerly known as Nine Express Limited (Stock Code: 0009), Sincere Watch (Hong Kong) Limited (Stock Code: 0444), Baijin Life Science Holdings Limited (formerly known as Affluent Partners Holdings Limited) (Stock Code: 1466), Coolpad Group Limited (Stock Code: 2369), and Kingston Financial Group Limited (Stock Code: 1031) (the securities of which were listed on the Stock Exchange and delisted in February 2023).

Mr. CHIU holds a Master of Accountancy (MAcc) from The Chinese University of Hong Kong, an Executive Master of Professional Accountancy (EMPAcc) and a Chief Financial Officer (CFO) qualification from the National Accounting Institute of Shanghai, a Master of Commerce (Mcom) from the University of New South Wales in Australia, a Bachelor of Laws (LLB) from Peking University, a Bachelor of Administrative Studies (BAS) and a Bachelor of Arts (BA) in Economics from York University in Canada.

Mr. CHIU has not entered into any service contract for his duties as the executive Director with the Company. He will be entitled to receive an annual director's fee of HK\$60,000 which was determined by the Board based on recommendation of the remuneration committee of the Company and with reference to his relevant roles, duties and responsibilities in the Company, the prevailing market conditions and the Company's performance. He is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the articles of association of the Company.

As at the date of this announcement, Mr. CHIU is indirectly interested in 547,609,590 non-voting convertible preference shares of the Company under his wholly controlled corporation, Creative Big Limited. Save as disclosed above, Mr. CHIU (i) does not hold any interest in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong); (ii) does not hold any directorship in any Hong Kong or overseas listed public companies in the last three years; and (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholder(s) (as defined in the Rules (the "**GEM Listing Rules**") Governing the Listing of Securities on GEM of the Stock Exchange) of the Company nor does he hold any position in the Company or any of its subsidiaries.

Mr. CHIU was an independent non-executive director of Keyne from 23 June 2015 to 1 July 2022. As disclosed in the regulatory announcement published by the Stock Exchange on 9 May 2023 (the "**Regulatory Announcement**"), the Listing Committee (the "**Listing Committee**") of the Stock Exchange criticised, inter alia, Mr. CHIU as a former independent non-executive director of Keyne for breaches of his obligations under the Declaration and Undertaking given to the Stock Exchange for failing to use his best ability to comply with the Rules (the "**Listing Rules**") Governing the Listing of Securities on the Stock Exchange and procure Keyne to comply with the Listing Rules, particularly with regard to the disclosure in announcement and delay in publication of major and connected transactions. For details, please refer to the Regulatory Announcement, which can be found on the website of the Stock Exchange.

Apart from the direction of the Listing Committee in the Regulatory Announcement requiring Mr. CHIU to attend 26 hours of training on regulatory and legal topics including the compliance of the Listing Rules, which Mr. CHIU confirmed he has duly completed, no further action was taken against Mr. CHIU by the Stock Exchange in relation to the subject matter. Given Mr. CHIU's education, background and experience, the Board considers that Mr. CHIU is a suitable candidate for the positions as an executive Director and a member of the nomination committee and the remuneration committee of the Company.

Save as disclosed above, neither any further information is required to be disclosed pursuant to the requirements under Rule 17.50(2)(h) to (v) of the GEM Listing Rules nor any other matter relating to the appointment of Mr. CHIU is needed to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its warmest welcome to Mr. CHIU for joining the Company.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
HO Kam Kin
Executive Director

Hong Kong, 2 June 2025

As at the date of this announcement, the Board comprises Mr. CHIU Sin Nang Kenny, Mr. HO Kam Kin and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence, Mr. HSU Dong An and Mr. HEUNG Pik Lun as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at <https://www.hkexnews.hk> for a minimum period of 7 days from the date of its publication and on the website of the Company at <http://www.sinopharmtech.com.hk>.